FDA Inspection
Avista Pharma Solutions, Inc. dba CambrexAvista Pharma Solutions, Inc. dba Cambrex – FDA Inspection, Jul 17, 2020
Record Details
This FDA Inspection record concerns Avista Pharma Solutions, Inc. dba Cambrex, with an inspection on July 17, 2020, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- July 17, 2020
- Product Type
- Drugs
View Company Profile
ID · ee45f26b-b044-435f-9d45-4363448c47de
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1128465
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Avista Pharma Solutions, Inc. dba Cambrex
3| Date | Classification | Office | Project area |
|---|---|---|---|
| July 3, 2025 | Not classified | Atlanta District Office | |
| October 30, 2012 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 9, 2009 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Avista Pharma Solutions, Inc. dba Cambrex
- FDA Inspection 1277419 - 2025-07-03
- FDA Inspection 805222 - 2012-10-30
- FDA Inspection 636454 - 2009-10-09
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.